Fault-tolerant hyperbolic Floquet quantum error correcting codes

A central goal in quantum error correction is to reduce the overhead of fault-tolerant quantum computing by increasing noise thresholds and reducing the number of physical qubits required to sustain a logical qubit. We introduce a potential path towards this goal based on a family of dynamically generated quantum error correcting codes that we call "hyperbolic Floquet codes." These codes are defined by a specific sequence of non-commuting two-body measurements arranged periodically in time that stabilize a topological code on a hyperbolic manifold with negative curvature. We focus on a family of lattices for $n$ qubits that, according to our prescription that defines the code, provably achieve a finite encoding rate $(1/8+2/n)$ and have a depth-3 syndrome extraction circuit. Similar to hyperbolic surface codes, the distance of the code at each time-step scales at most logarithmically in $n$. The family of lattices we choose indicates that this scaling is achievable in practice. We develop and benchmark an efficient matching-based decoder that provides evidence of a threshold near 0.1% in a phenomenological noise model. Utilizing weight-two check operators and a qubit connectivity of 3, one of our hyperbolic Floquet codes uses 400 physical qubits to encode 52 logical qubits with a code distance of 8, i.e., it is a $[[400,52,8]]$ code. At small error rates, comparable logical error suppression to this code requires 5x as many physical qubits (1924) when using the honeycomb Floquet code with the same noise model and decoder.Comment: 15 pages, 7 figure

Difference-Masking: Choosing What to Mask in Continued Pretraining

The self-supervised objective of masking-and-predicting has led to promising performance gains on a variety of downstream tasks. However, while most approaches randomly mask tokens, there is strong intuition that deciding what to mask can substantially improve learning outcomes. We investigate this in continued pretraining setting in which pretrained models continue to pretrain on domain-specific data before performing some downstream task. We introduce Difference-Masking, a masking strategy that automatically chooses what to mask during continued pretraining by considering what makes a task domain different from the pretraining domain. Empirically, we find that Difference-Masking outperforms baselines on continued pretraining settings across four diverse language-only and multimodal video tasks

Large expert-curated database for benchmarking document similarity detection in biomedical literature search

Document recommendation systems for locating relevant literature have mostly relied on methods developed a decade ago. This is largely due to the lack of a large offline gold-standard benchmark of relevant documents that cover a variety of research fields such that newly developed literature search techniques can be compared, improved and translated into practice. To overcome this bottleneck, we have established the RElevant LIterature SearcH consortium consisting of more than 1500 scientists from 84 countries, who have collectively annotated the relevance of over 180 000 PubMed-listed articles with regard to their respective seed (input) article/s. The majority of annotations were contributed by highly experienced, original authors of the seed articles. The collected data cover 76% of all unique PubMed Medical Subject Headings descriptors. No systematic biases were observed across different experience levels, research fields or time spent on annotations. More importantly, annotations of the same document pairs contributed by different scientists were highly concordant. We further show that the three representative baseline methods used to generate recommended articles for evaluation (Okapi Best Matching 25, Term Frequency-Inverse Document Frequency and PubMed Related Articles) had similar overall performances. Additionally, we found that these methods each tend to produce distinct collections of recommended articles, suggesting that a hybrid method may be required to completely capture all relevant articles. The established database server located at https://relishdb.ict.griffith.edu.au is freely available for the downloading of annotation data and the blind testing of new methods. We expect that this benchmark will be useful for stimulating the development of new powerful techniques for title and title/abstract-based search engines for relevant articles in biomedical research.Peer reviewe

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

UBC Okanagan general workshop template

This project supports Open Science activities offered by UBC's Okanagan Campus

Analysis

Computed data

Protocol

Procedures, including required equipment, instruments, safety precautions, and reporting standards

Literature Review

Bibliography and literature synthesis

Data

Raw and refined